MDM2 and small cell lung carcinoma: Furthermore, in a cohort of 3,600 SCLC samples submitted for broad targeted next-generation sequencing (tNGS) at Foundation Medicine, 5.5% were reported to lack RB1 and TP53 alterations; this subset harbored instances of CCND1 and MDM2 amplification, but no WGS or detailed clinicopathologic characterization of these samples was available (3).